Showing 4581-4590 of 6978 results for "".
- Merz North American Provides Educational Grant to Support Dermatology Board Review Systemhttps://practicaldermatology.com/news/20140327-merz_north_american_provides_education_grant_to_support_dermatology_board_review_system/2459291/Merz North America recently provided an educational grant to fund the Derm In-Review system that helps residents prepare for their Board certifying exams free of charge. The system, which has helped prepare more
- Quinnova Pharmaceuticals Announces the Launch of Ecoza Foamhttps://practicaldermatology.com/news/20140319-quinnova_pharmaceuticals_announces_the_launch_of_ecoza_foam/2459310/Quinnova Pharmaceuticals LLC, an affiliate of Exeltis, launched its recently FDA-approved Ecoza (econazole nitrate) topical foam 1%. Ecoza Foma is indicated for the treatment of inter
- Upcoming Events to Educate PAs and NPs about Psoriasishttps://practicaldermatology.com/news/20140310-upcoming_events_to_educate_pas_and_nps_about_psoriasis/2459321/Nurse practitioners and physician assistants aiming to deepen their understanding of psoriasis can attend upcoming events sponsored by the The National Psoriasis Foundation. The Nurse Practitioner Psoriasis Symposium, a joint symposium from the
- Ellman to Launch PelleFirm at Annual Meeting of the AADhttps://practicaldermatology.com/news/20140227-ellman_to_launch_pellefirm_at_annual_meeting_of_the_aad/2459327/Ellman International, Inc., received FDA clearance to market its new PelleFirm RF Body Treatment System. The PelleFirm System is CE Marked for body skin tightening and cellulite reduction. In addition, it also has received FDA 510(K) clearance for tissue heating and the temporar
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Eclipse Sun Launches New Line of Sun Protective Clothing for Babies and Kidshttps://practicaldermatology.com/news/20140220-eclipse_sun_launches_new_line_of_sun_protective_clothing_for_babies_and_kids/2459336/Eclipse Sun Products announced the introduction of its new line of sun protective clothing made especially for babies and kids. The
- Everett Laboratories Acquires Quinnova Pharmaceuticalshttps://practicaldermatology.com/news/20140123-everett_laboratories_acquires_quinnova_pharmaceuticals/2459363/Everett Laboratories, Inc., a privately held specialty pharmaceutical company and a subsidiary of Exeltis, headquartered in
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according t
- Practical Dermatology® Magazine Names Neal Bhatia, MD, FAAD Co-Chief Medical Editorhttps://practicaldermatology.com/news/20140117-practical_dermatology_magazine_names_neal_bhatia_md_faad_co-chief_medical_editor/2459367/Neal Bhatia, MD, FAAD, San Diego-based dermatologist and well known lecturer and author, has been named Co-Chief Medical Editor of Practical Dermatology® magazine from Bryn Mawr Communications III, LLC. Now in it's 11th year of publicat
- Rosacea Survey: Emotional Impact of Rosacea as Significant and Visible Signshttps://practicaldermatology.com/news/20140116-rosacea_survey_emotional_impact_of_rosacea_as_significant_and_visible_signs/2459371/The emotional impact of rosacea is often substantial regardless of subtype or severity, according to results of a new survey of 1,675 rosacea patients conducted by the National Rosacea Society. Among survey respondents who suffer from the facial redn